Micro Emerging Active

JNJ ICOTYDE psoriasis trial results

Score
0.2
Velocity
▲ 0.0
Articles
1
Sources
1

Summary

An article belongs to this narrative if it covers Johnson & Johnson's ICOTYDE (icotrokinra) Phase 3 trial results for treating moderate-to-severe plaque psoriasis.

Related Articles

Johnson & Johnson Reports Strong Long-Term Results For ICOTYDE In Plaque Psoriasis

Nasdaq · Mar 28, 2026
Mixed

Sources

Johnson & Johnson Reports Strong Long-Term Results For ICOTYDE In … Nasdaq

Timeline

Last Updated Mar 28, 2026